Sharda Cropchem Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹7,569 Cr
- Book Value
- ₹347
- Stock P/E
- 12.1
- Dividend Yield
- 1.78%
- ROE
- 23.2%
- ROCE
- 30.3%
- PEG Ratio
- 0.51
- EV/EBITDA
- 6.4
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Sharda Cropchem share price today
Sharda Cropchem (NSE: SHARDACROP) runs agrochemicals’ most misunderstood model: it owns no plants. Its asset is a library of 4,000+ product registrations — the regulatory licences to sell generic crop-protection molecules across Europe, the Americas and beyond — earned through years-long, capital-cheap dossier work. Manufacturing is sourced (mostly China), branding is local, and the registration library does what factories cannot: it compounds, transfers nowhere, and depreciates never.
The market’s chronic suspicion of the model is the price: 12.1× earnings, PEG 0.51, EV/EBITDA 6.4 — for a business earning 30.3% ROCE with zero debt and paying 1.78%. Our universe tags it accumulate: our note calls it the value pick of the small-cap list, flags attached (China sourcing, generic-pricing margin swings).
The registration library
Each registration is a mini-moat: country-by-country regulatory approval that takes years and specialist skill to earn, then sells product against it indefinitely. Sharda’s pipeline keeps adding registrations (the true capex line), and the spread between China sourcing costs and Western generic prices is the margin engine — volatile quarter to quarter (the flags are honest), structurally positive across cycles. Working capital, not factories, is the balance-sheet story; net cash keeps it comfortable.
Watch-items: agrochem generic pricing (the margin swing), China supply-chain continuity, registration-pipeline additions, and European agricultural policy shifts.
The numbers
From our research universe snapshot (5 Aug 2026):
| Metric | Value |
|---|---|
| Market cap | ₹7,569 Cr |
| P/E (TTM) | 12.1 |
| EV/EBITDA | 6.4 |
| Operating margin | 19.5% |
| ROE / ROCE | 23.2% / 30.3% |
| Debt to equity | 0.00 (net cash) |
| Sales CAGR (5y) | 17.1% |
| Profit CAGR (5y) | 23.8% |
| Promoter holding | 74.8% |
| EPS (TTM) | ₹69.53 |
Sharda Cropchem share price target 2026 to 2030
EPS base ₹69.53 (TTM). Bear: generic pricing turns down again — 4% growth, multiple at 8×. Base: the library compounds normally — 12% growth at 11×. Bull: an agrochem upcycle re-rates the model — 18% growth at 14×.
| Year | Bear (8×, +4%) | Base (11×, +12%) | Bull (14×, +18%) |
|---|---|---|---|
| 2026 | ₹578 | ₹857 | ₹1,150 |
| 2027 | ₹602 | ₹959 | ₹1,355 |
| 2028 | ₹626 | ₹1,075 | ₹1,600 |
| 2029 | ₹651 | ₹1,205 | ₹1,885 |
| 2030 | ₹677 | ₹1,350 | ₹2,225 |
From ₹841, the base case is ≈ +60% over four and a half years plus the 1.78% yield; the bear is −19%. At 12×, the cyclical risk is substantially prepaid — accumulate arithmetic on a misunderstood model.
Reasons to own Sharda Cropchem (at the right price)
- A 4,000-registration library — regulatory moats that compound without capex.
- 30% ROCE, net cash, zero factories to depreciate or maintain.
- 12× with PEG 0.51 — the market’s suspicion is the entry discount.
- Generic crop-protection demand is structural: patents keep expiring.
- A 1.78% yield funded by a working-capital-light model.
The risks: margins swing with China sourcing costs and Western generic pricing, geopolitical supply-chain shocks hit the model’s core, and asset-light businesses get no asset-value floor in panics.
Should you buy at the current price?
The live buy range below is for members — the library at a paperback price.
FAQ
What is the Sharda Cropchem share price target for 2030? Base case ≈ ₹1,350 (11× on 12% compounded growth), bear ≈ ₹677, bull ≈ ₹2,225. Arithmetic above.
How does a company with no plants earn 30% ROCE? The capital is the registration library and working capital, both modest against the profits the licences enable — asset-light economics agrochemicals rarely see.
Why does the market keep it this cheap? China-sourcing dependence, margin volatility, and a model that doesn’t fit standard chemical-sector templates. The accumulate case is that 12× over-discounts all three.
When are Sharda Cropchem’s next results? Track the exact date on our results calendar.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.